Last reviewed · How we verify
NCT05414851
Low-Carbohydrate and Plant-Based Dietary Effects on Vascular Health
NA trial testing Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet in Heart Disease, Ischemic in 45 participants. Completed in 23 April 2024.
23 April 2024
Quick facts
| Lead sponsor | University of Rochester |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 20 December 2022 |
| Primary completion | 23 April 2024 |
| Estimated completion | 23 April 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet
Conditions studied
- Heart Disease, Ischemic — all drugs for Heart Disease, Ischemic →
- Hyperlipidemias — all drugs for Hyperlipidemias →
- Hypertension — all drugs for Hypertension →
Sponsor
University of Rochester
Who can join
50 and older, any sex, with Heart Disease, Ischemic or Hyperlipidemias. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized trial with a crossover design to investigate the short-term effects of two different dietary patterns on markers of vascular health. A low-carbohydrate diet and a whole-food, plant-based diet will be used. In addition to more traditional markers (cholesterol, blood pressure, inflammation), endothelial progenitor cells and trimethylamine N-oxide will be assessed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05414851
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Disease, Ischemic
Currently open trials in the same condition.
- NCT04179643 — AB-1002 in Patients With Class III Heart Failure · Phase 1 · active not recruiting
Other University of Rochester trials
Trials by the same sponsor.
- NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
- NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
- NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
- NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
- NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05414851 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rochester
- Last refreshed: 16 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05414851.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing